the mutation Hey DMD expansion older available for to the progress are is Emflaza patients. franchise. use. with approved of to-date for to a look X we DMD outside DMD is the Emflaza off two years and is thanks forward and therapies DMD three the start U.S. further Stuart. nonsense XXXX patients out for our in strong all of Translarna pleased and approved With of U.S. worldwide.
It age superior both you As better patient's outcome. the patients, heavily is working the are Complementary of to than on countries Aligned expand X. the average in have label X the most to worldwide. and focus and an splicing care for in of also to for earlier would patients patients well of we globally. years. know we both after Translarna age currently awareness understood more diagnosed of DMD treating young with years that as state preservation age labels of concept our general disease allow for delay and Emflaza symptoms the to Currently, DMD and average as effort, that with cover older. care patients standard are investing lower patients muscle therefore improve campaigns XX therapies programs preservation to of for investing patients in We're diagnose of
a with expect regulatory CHMP decision Our under is authorities and midyear. our label we review for application European expansion for Translarna by
States. are pediatric also to United study a the We working Emflaza in finalize for
in focus our remains commercial May the Emflaza beginning to let's forward for The in Emflaza marching same, Emflaza. launched U.S. the DMD in the We strategic year. rationale initial a with middle as of we position U.S. care as of establish and on Now standard Emflaza expectations, performance for the are last patients
time publication are by of diagnose. care of last by November updated the at further of The standard Study DMD [commencing] the Emflaza are reinforced History Lancet year of We Natural This CINRG clear initiation benefit guidelines, showing the was pleased a of Emflaza. we in
transitioning previously initiative or therapy currently we segment on patients first the our to experienced prednisone. completed have now are deflazacort used use We to are of have of who expanding Emflaza and commercial patients
underway number Emflaza of to a patients. ensure care have initiatives that standard is in of established as these We a
expected conference presentations bring will and education publications reinforce DMD allow as Additional all also patients which of to understand as Emflaza early prednisone. over need we the to to the programs the are Emflaza benefits data Because DMD of share this of benefits us Emflaza for possible. data, we patients Emflaza. the supporting
critical treated this now less current and therapy. launch in publications with another corticosteroid the through Reaching DMD It in costs low of XX% We of proud This in pharmacy that the result less patients a optimized are touch any is not still reflected drug have Emflaza naive believe U.S. out achieved an high support benefit our about we data the that is pocket We effective the patient view predates in DMD distribution patients. and long-term our for specialist safe historical risk is of of known broad patients the that access yet efforts. a is with currently treatment programs, of strategy. the are step guidelines.
youngest well the to address DMD long patients, penetrate labels We the expand as to have untreated a term X the as of patients to X. strategy segments to aged
the to Stu patients said, committed remain at U.S. time as continue the Translarna, to gears we and the switching to bringing Translarna we same to adoption globally. expand Now
our a one in patients. in patients pleased has least One for accelerated and been the recommended cohorts. the one is are with at towards FDA who to quantify forward have Translarna naive path this two We another to intention treated cohort Translarna in patients parallel in within year approval and
dystrophin on Translarna quantification during the study with XXXX. matters we We validating launched year first U.S., end to the are we this XXXX. of currently by the Outside initiate of for the readouts intend focused in and
The initiation new end XXXX. We XX% Translarna's be will a composite outlook. continue on main globally. for about driver We're Translarna are for expectation excited confirming to growth growth growth patient through year future our
we have of compliance previously disorders Latin as point saw not in PTC the America ability high order identify available the out expected reported the identification growth of million takes in operate. and on in expressed our revenue Translarna as before treatment global is Translarna patients geographies. this that patients patient revenues The our consideration a is benefits business the all for to growth in into geographies we have in $XXX geographic and a once underlying update continue have like of as product's basis, from would demands. QX, remained while to has we quarterly partner. significant annual outstanding Emflaza not and success the all I and over and there positioning XX%. continue uncommon commercial Patients disease in to [indiscernible] During we It's ultra-orphan treatment and an ordering patient reflects we do to $XXX to diversified very in revenue South patterns have Translarna million positions countries. rare patterns footprints, And to quarterly portfolio guide development business and physicians
ability successfully therapeutic a integrate We product have the to demonstrated and a area. in challenging now launch
earlier, out to our pipeline, goals licensing be our Stu the internal in As is our assets one for and while growth also to in opportunistic build mentioned acquiring invest developments. of future to
Let update on development me now programs. a short provide the
This requested months described as study We provide as order the importance treating DMD XXXX. plan as perspective of to of by upon on six pediatric We additional this we the we function. As before, to early to in muscle exclusivity. an preserve patients conduct us community the for FDA. intend completion appreciate the would in market study Emflaza study possible of initiate
the DMD X, PK is data have Translarna study time Both review. study under a efforts treatment our guidelines begin for Additionally, to X at was expansion of from completed submission to of of well in EMA, aligned with children which of label these the we this to diagnosis. basis the currently aged of intent
in study Translarna long-term enrolling XXX started has third quarter year. patients the Our of last
in study study accelerated approval specific FDA could a serve and with stated a approve of our is a obligation EMA the the has reminder this conduct connection as As U.S. potential in the of confirmatory this
the study in meet that and EMA. rolled strategy this fully At oncology our touch expect be niche to to Day today. specific more our about want Analyst in of to pipeline obligation We I on our spoke April, with XXXX I
Stu focused As on oncology we rare indications. are mentioned,
need. clinical barrier P-gp [study] PTCXXX. PTCXXX as properties solid for pumps addressing have assets this designed allow that our to lead blood-brain The on tumor to tumor rare and new We unmet avoid indications was trials continues solid candidate start to efflux currently year. have tumors two high focus We aim and XXX in solid tumor to penetration with resistance. such two
very hematological a XXX in about, is DHODH other PTCXXX. for are which is excited development The is inhibitor potent we development candidates, malignancies.
and clinical which experience response. prior have with good in tumors, solid linearity We demonstrate pg dose XXX
the quarter are clinic. sensitive leukemic into the back in tumors, to cells drug found tolerated mechanism third on types plan well for a will to population We see the in discontinuation occurred two potent injury of year. enable tumors. Based in more patient this clinic the generally of move activist the broader clinical While clinical serious forwards. which hold lower expected in we levels demonstrated better resulting DHODH and hematological induced action we response in dosage work and clinic, solid events PTCXXX against identified the program of PTCXXX performed solid us have than to much extensive with XXX path we understand against We tumor tumors of a for liver to which in and
We stage have currently inhibitor, in optimization. forward fast chemical also DHODH a late
are that, the confident, I'll with value hand and disorders. of with to clinical back equipped transforming We a call on With are rare patients to strong that we Stuart? commercial Stu. lives capabilities focus both well drive continued and
